

UNIVERSITI TEKNOLOGI MARA

**SAFETY AND EFFICACY OF WARFARIN IN
TREATING PATIENTS WITH ATRIAL
FIBRILLATION IN SARAWAK GENERAL
HOSPITAL HEART CENTER**

NUR ANNISA BINTI MOHAMMED ISMAIL

**Dissertation submitted in partial fulfillment of the requirement for
the Bachelor of Pharmacy (Hons.)**

Faculty of Pharmacy

July 2016

ACKNOWLEDGEMENT

First of all, I would like to thank Allah S.W.T for making it possible for me to complete this thesis successfully. I would also like to convey my deepest appreciation to Madam Shazwani Bt Shaharuddin, my supervisor, for her endless guidance and support that she has given me. My gratitude also goes to Dr Lawrance Anchah, Mr. Ahmad Ramdhani B. Abd Manan and Miss Ku Ming Ying, pharmacists from Sarawak General Hospital Heart Center for their guidance and assistance throughout the period of data collecting. I would also like to thank all the staffs of Sarawak General Hospital Heart Center and Faculty Pharmacy of UiTM. A special thank goes to my parents, Mohammed Ismail Fauzi and and my family for their love, support and motivation in order for me to finish this thesis. Not forgetting my fellow friends, Amirah Bahrain, Filza Najiha and and Nur Najihah for all the support and friendship.

Last but not least, I would like to thank anyone and everyone who have helped me in the completion of this thesis. Thank you.

TABLE OF CONTENTS

	Page
TITLE PAGE	
ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS	iii
LIST OF TABLES	iv
LIST OF FIGURES	v
ABSTRACT	vi
 CHAPTER ONE (INTRODUCTION)	
1.1 Background of study	1
1.2 Problem statement	3
1.3 Objectives	3
1.4 Significance of study	3
 CHAPTER TWO (LITERATURE REVIEW)	
2.1 Atrial fibrillation	4
2.2 History of warfarin	6
2.3 Pharmacology of warfarin	7
2.4 International Normalised Ratio (INR)	8
2.5 Time in Therapeutic Range (TTR)	11
2.6 Ethnicity and race differences	12
2.7 Interactions	13
2.8 CHADS ₂ score	17
2.9 HAS-BLED score	19
 CHAPTER THREE (METHODOLOGY)	
3.1 Method	21
3.2 Inclusion criteria	21
3.3 Exclusion criteria	21
3.4 Outcome measures	22
3.5 Data collection	22
3.6 Data analysis	22
 CHAPTER FOUR (RESULTS AND DISCUSSION)	
4.1 Patients Demographic Information	23
4.2 International Normalised Ratio	25
4.3 Time in Therapeutic Range	27
4.4 CHADS ₂ score	28
4.5 HAS-BLED score	32
4.6 Limitation	34
 CHAPTER FIVE (CONCLUSION)	35
 BIBLIOGRAPHY	36

ABSTRACT

Atrial fibrillation is a condition where the heart does not beat regularly. This condition is usually treated with warfarin to prevent the risk of blood clotting and bleeding. Warfarin has narrow therapeutic window. Thus, monitoring is needed and international normalised ratio (INR) is used for this purpose. From the INR readings, time in therapeutic range (TTR) is calculated to evaluate the quality of the anticoagulant. 120 patients with atrial fibrillation were randomly selected and their INR readings were recorded. At least four INR readings were inserted into INR template to obtain the TTR. 61 males and 59 females were involved. 25.8% of the patients were 75 years old and above while the remaining 74.1% were with the age of 74 and below. 73% of the patients have TTR less than 75% while the remaining 27% have TTR 75% and above. Warfarin prescribing should be taken seriously to increase the TTR and minimize risk of developing stroke or bleeding.

CHAPTER 1

INTRODUCTION

1.1 Background of study

Atrial fibrillation (AF) is the irregular rhythm of the heartbeat. It happens when an electrical impulse from the sinoatrial (SA) node in the atria is generated abnormally. This will cause the ability of the atria to pump blood into the ventricle to reduce. As a result, the heart will pump more rapidly (Kulick, 2015). As the rhythm of heart is abnormal, there is risk of blood pooling as the blood starts to move and circulate slowly. This can lead to formation of blood clot, which eventually can lead to stroke ("Atrial Fibrillation," n.d). The AF prevalence in Malaysia was calculated as 2.8% (Freestone, Rajaratnam, Hussain, & Lip, 2003).

Stroke is a condition where the oxygen supply to the brain is being obstructed. According to World Health Organization (WHO), stroke is defined as the clinical syndrome of rapid onset of focal (or global, as in subarachnoid haemorrhage) cerebral deficit, lasting more than 24 hours or leading to death, with no apparent cause other than a vascular one (Warlow et al., 2003). Hospital admission due to stroke associated with AF in Malaysia in 2012 was reported to be 3.1% to 24.2% (Guo, Lip, & Apostolakis, 2012). In the event of atrial fibrillation and hypercoagulability, the risk of developing stroke increases as both AF and hypercoagulability are associated with atrial thrombogenesis and embolism (O'Neal